Raymond James downgraded Jounce Therapeutics to Market Perform from Outperform without a price target. The company is restructuring with a 57% workforce reduction and noted JTX-8064 did not demonstrate clinical activity "sufficient to create the value necessary for Jounce to independently advance these programs to the next stage of development," the analyst tells investors in a research note. The firm says it is "over for the constructive thesis on JTX-8064."
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JNCE:
- Redx and Jounce Announce Recommended Business Combination
- Jounce Therapeutics Announces Restructuring
- Jounce Therapeutics to reduce workforce by 57%
- Piper Sandler keeps Overweight on Jounce Therapeutics, lowers price target to $5
- Biotech Alert: Searches spiking for these stocks today
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue